If Cytodyn is not testing for PD-L1 expression in our cancer trials they should be. CCR5 blockade downregulates PD-L1 and it would be helpful to know how well leronlimab does it. If it does it sufficiently we beat out Keytruda's PD-1 inhibition just on that alone.